|
시장보고서
상품코드
2030820
성병(STD) 치료 시장(2026-2030년)Global Sexually Transmitted Diseases (STD) Treatment Market 2026-2030 |
||||||
세계의 성병(STD) 치료 시장은 2025-2030년 268억 550만 달러 증가하고, 예측 기간 중 연평균 복합 성장률(CAGR)은 7.2%를 나타낼 것으로 예측됩니다.
세계의 성병(STD) 치료 시장에 대해 조사 분석했으며, 시장 규모와 예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더 분석 등의 정보를 전해드립니다.
이 보고서는 현재 시장 상황, 최신 동향 및 성장요인, 그리고 전체 시장 환경에 대한 최신 분석을 제공합니다. 이 시장은 분자진단 및 현장 검사 기술 발전, 장기 지속형 주사 요법 및 새로운 항바이러스 제제의 확대, 공중 보건에 대한 인식 증가, 정부 주도의 예방 조치에 힘입어 성장하고 있습니다.
이번 조사는 업계 주요 관계자들의 의견을 포함한 1차 정보와 2차 정보를 객관적으로 조합하여 실시되었습니다. 이 보고서에는 주요 기업 분석과 함께 종합적인 시장 규모 데이터, 지역별 분석과 함께 부문 및 공급업체 현황이 포함되어 있습니다. 보고서에는 과거 데이터와 예측 데이터가 수록되어 있습니다.
| 시장 범위 | |
|---|---|
| 기준연도 | 2025년 |
| 종료연도 | 2030년 |
| 조사 기간 | 2026-2030년 |
| 성장 모멘텀 | 가속 |
| 2026년 전년대비 | 6.7% |
| CAGR | 7.2% |
| 증가액 | 268억 550만 달러 |
이 보고서는 차세대 백신 및 면역 요법의 개발이 향후 몇 년 동안 세계 성병(STD) 치료 시장의 성장을 주도할 주요 요인 중 하나로 꼽았습니다. 또한, 표적 항균제 내성(AMR) 대책과 병용요법의 등장, 통합 원격의료 생태계와 디지털 처방 플랫폼의 부상으로 인해 시장에서 상당한 수요가 발생할 것으로 예측됩니다.
목차
제1장 주요 요약
제2장 Technavio 분석
제3장 시장 구도
제4장 시장 규모
제5장 시장 규모 실적
제6장 정성 분석
제7장 Five Forces 분석
제8장 시장 세분화 : 유형별
제9장 시장 세분화 : 투여 경로별
제10장 시장 세분화 : 최종사용자별
제11장 고객 현황
제12장 지역별 상황
제13장 성장 촉진요인, 과제 및 기회
제14장 경쟁 구도
제15장 경쟁 분석
제16장 부록
LSH 26.05.28The global sexually transmitted diseases (STD) treatment market is forecasted to grow by USD 26805.5 mn during 2025-2030, accelerating at a CAGR of 7.2% during the forecast period. The report on the global sexually transmitted diseases (STD) treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by technological advancements in molecular diagnostics and point-of-care testing, expansion of long-acting injectable therapies and novel antiviral formulations, increasing public health awareness and government-led preventive initiatives.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 6.7% |
| CAGR | 7.2% |
| Incremental Value | $26805.5 mn |
Technavio's global sexually transmitted diseases (STD) treatment market is segmented as below:
By Type
- Viral infections
- Bacterial infections
- Others
By Route Of Administration
- Oral
- Topical
- Injectable
By End-User
- Hospital and clinics
- Diagnostic centers
- Individuals
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the development of next-generation vaccines and immunotherapeutic interventions as one of the prime reasons driving the global sexually transmitted diseases (STD) treatment market growth during the next few years. Also, emergence of targeted antimicrobial resistance (AMR) solutions and combination therapies and rise of integrated telehealth ecosystems and digital prescription platforms will lead to sizable demand in the market.
The report on the global sexually transmitted diseases (STD) treatment market covers the following areas:
- Global sexually transmitted diseases (STD) treatment market sizing
- Global sexually transmitted diseases (STD) treatment market forecast
- Global sexually transmitted diseases (STD) treatment market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global sexually transmitted diseases (STD) treatment market vendors that include AbbVie Inc., Aurobindo Pharma Ltd., Bavarian Nordic AS, Bristol Myers Squibb Co., Cipla Inc., Dr. Reddys Laboratories Ltd., Evofem Biosciences Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Inovio Pharmaceuticals Inc., Johnson and Johnson Services, Merck and Co. Inc., Pfizer Inc., Sandoz Group AG, Sanofi SA, Sun Pharmaceutical Industries, Teva Pharmaceutical Ltd., Viatris Inc.. Also, the global sexually transmitted diseases (STD) treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Sexually Transmitted Diseases (STD) Treatment Market 2020 - 2024
- Historic Market Size - Data Table on Global Sexually Transmitted Diseases (STD) Treatment Market 2020 - 2024 ($ million)
- 5.2 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ million)
- 5.3 Route of Administration segment analysis 2020 - 2024
- Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
- 5.4 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on global sexually transmitted diseases (STD) treatment market
- 6.2 Impact of geopolitical conflicts on global sexually transmitted diseases (STD) treatment market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Type
- 8.1 Market segments
- 8.2 Comparison by Type
- 8.3 Viral infections - Market size and forecast 2025-2030
- 8.4 Bacterial infections - Market size and forecast 2025-2030
- 8.5 Others - Market size and forecast 2025-2030
- 8.6 Market opportunity by Type
- Market opportunity by Type ($ million)
9 Market Segmentation by Route of Administration
- 9.1 Market segments
- 9.2 Comparison by Route of Administration
- 9.3 Oral - Market size and forecast 2025-2030
- 9.4 Topical - Market size and forecast 2025-2030
- 9.5 Injectable - Market size and forecast 2025-2030
- 9.6 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
10 Market Segmentation by End-user
- 10.1 Market segments
- 10.2 Comparison by End-user
- 10.3 Hospital and clinics - Market size and forecast 2025-2030
- 10.4 Diagnostic centers - Market size and forecast 2025-2030
- 10.5 Individuals - Market size and forecast 2025-2030
- 10.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Turkey - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 Colombia - Market size and forecast 2025-2030
- 12.6.7 South Africa - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Technological advancements in molecular diagnostics and point-of-care testing
- Expansion of long-acting injectable therapies and novel antiviral formulations
- Increasing public health awareness and government-led preventive initiatives
- 13.2 Market challenges
- Escalation of multidrug-resistant pathogens and limitation of pharmaceutical pipelines
- Pervasive social stigma and its impact on screening and treatment adherence
- Significant health disparities and inequitable access to specialized diagnostic infrastructure
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Development of next-generation vaccines and immunotherapeutic interventions
- Emergence of targeted antimicrobial resistance (AMR) solutions and combination therapies
- Rise of integrated telehealth ecosystems and digital prescription platforms
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Segment focus
- SWOT
- 15.5 Aurobindo Pharma Ltd.
- Aurobindo Pharma Ltd. - Overview
- Aurobindo Pharma Ltd. - Business segments
- Aurobindo Pharma Ltd. - Key news
- Aurobindo Pharma Ltd. - Key offerings
- Aurobindo Pharma Ltd. - Segment focus
- SWOT
- 15.6 Cipla Inc.
- Cipla Inc. - Overview
- Cipla Inc. - Business segments
- Cipla Inc. - Key news
- Cipla Inc. - Key offerings
- Cipla Inc. - Segment focus
- SWOT
- 15.7 Dr. Reddys Laboratories Ltd.
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key news
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Segment focus
- SWOT
- 15.8 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.9 Gilead Sciences Inc.
- Gilead Sciences Inc. - Overview
- Gilead Sciences Inc. - Business segments
- Gilead Sciences Inc. - Key offerings
- Gilead Sciences Inc. - Segment focus
- SWOT
- 15.10 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 15.11 Hikma Pharmaceuticals Plc
- Hikma Pharmaceuticals Plc - Overview
- Hikma Pharmaceuticals Plc - Business segments
- Hikma Pharmaceuticals Plc - Key news
- Hikma Pharmaceuticals Plc - Key offerings
- Hikma Pharmaceuticals Plc - Segment focus
- SWOT
- 15.12 Johnson and Johnson Services
- Johnson and Johnson Services - Overview
- Johnson and Johnson Services - Business segments
- Johnson and Johnson Services - Key news
- Johnson and Johnson Services - Key offerings
- Johnson and Johnson Services - Segment focus
- SWOT
- 15.13 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 15.14 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- 15.15 Sandoz Group AG
- Sandoz Group AG - Overview
- Sandoz Group AG - Business segments
- Sandoz Group AG - Key news
- Sandoz Group AG - Key offerings
- Sandoz Group AG - Segment focus
- SWOT
- 15.16 Sun Pharmaceutical Industries
- Sun Pharmaceutical Industries - Overview
- Sun Pharmaceutical Industries - Business segments
- Sun Pharmaceutical Industries - Key news
- Sun Pharmaceutical Industries - Key offerings
- Sun Pharmaceutical Industries - Segment focus
- SWOT
- 15.17 Teva Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd. - Overview
- Teva Pharmaceutical Ltd. - Business segments
- Teva Pharmaceutical Ltd. - Key news
- Teva Pharmaceutical Ltd. - Key offerings
- Teva Pharmaceutical Ltd. - Segment focus
- SWOT
- 15.18 Viatris Inc.
- Viatris Inc. - Overview
- Viatris Inc. - Business segments
- Viatris Inc. - Key news
- Viatris Inc. - Key offerings
- Viatris Inc. - Segment focus
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
